CraniUS Therapeutics

CraniUS operates at the intersection of cranial implants, neurosurgery, and central-nervous-system drug delivery. Its differentiation is the combination of a patient-specific cranial implant with a skull-embedded, MRI-Conditional platform intended to provide repeatable direct-to-brain access while bypassing the blood-brain barrier. That model differs from conventional systemic administration, which can limit delivery into the brain, and from standalone cranial reconstruction products that do not provide a therapeutic-delivery pathway. The company’s September 2026 FDA 510(k) clearance for the CraniUS Plate gives it a concrete commercial entry point, while NeuroPASS remains the higher-risk platform opportunity requiring further clinical and commercialization progress.

CraniUS has followed a staged progression from formation and early financing to platform development and initial commercialization. Founded in 2021, it raised a $500,000 Seed round in August of that year, followed by a $19.4 million Series A in September 2022. A $1 million Maryland Department of Commerce grant in June 2024 supported continued neurotechnology development. The January 2026 Series B added $20 million, creating the financial base for advancing NeuroPASS toward commercialization, while the June 2026 NIH award added $1.1 million initially with potential support of up to $4 million. The September 9, 2026 FDA 510(k) clearance and U.S. commercial availability of the CraniUS Plate mark the most important operating inflection point so far. Board expansion through Oray B. Boston Jr. in February 2026 also suggests preparation for clinical and commercial execution. Growth evidence is stronger in capital formation and regulatory progress than in disclosed headcount, revenue, or clinical outcomes; the company remains listed in the 11-to-50 employee range.